BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...Inc. appointed Mark Iwicki as chairman. Iwicki, who currently serves as chairman and CEO of Kala Pharmaceuticals Inc....
BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

...alfa (AMG 592).FDA approves Kala’s dry eye drug; shares tumbleFDA approved Eysuvis loteprednol 0.25% from Kala Pharmaceuticals Inc....
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...a very selective buying opportunity. For instance, Linimeier said his firm added a position in Kala Pharmaceuticals Inc....
BioCentury | Mar 12, 2020
Finance

March 11 Quick Takes: PDL, Kala, InnoCare, LifeSci, BioSight, BillionToOne, SEC

...Officer and acting CFO Edward Imbrogno will become the permanent CFO. Kala raises $126M follow-on Kala Pharmaceuticals Inc....
...that they will utilize the extension and summarizing why it is needed. BioCentury Staff InnoCare Pharma Ltd. BioSight Ltd. Kala Pharmaceuticals Inc. PDL...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...of $40.78 on Tuesday, before the takeout was announced. Setback for Kala’s dry eye treatment Kala Pharmaceuticals Inc....
...etabonate mucosal penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala Pharmaceuticals Inc. miRagen...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...assessed to be at imminent risk for suicide Phase III data; submit sNDA 2H19; 4Q19 Kala Pharmaceuticals Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA) PDUFA date 3/20/19 Kala Pharmaceuticals Inc....
BioCentury | Dec 26, 2018
Company News

FDA accepts Acer, Kala NDAs before funding lapse

...FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial...
...up 17% to $5.02. Allison Johnson Edsivo, celiprolol (ACER-002) Inveltys, LE-MPP, Loteprednol etabonate mucosal penetrating particle (KPI-121) Acer Therapeutics Inc. Kala Pharmaceuticals Inc. Adrenergic...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...sleepiness in patients with obstructive sleep apnea and narcolepsy PDUFA date; submit MAA 12/20/18; YE18 Kala Pharmaceuticals Inc....
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy Kala Pharmaceuticals Inc....
Items per page:
1 - 10 of 56
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...Inc. appointed Mark Iwicki as chairman. Iwicki, who currently serves as chairman and CEO of Kala Pharmaceuticals Inc....
BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

...alfa (AMG 592).FDA approves Kala’s dry eye drug; shares tumbleFDA approved Eysuvis loteprednol 0.25% from Kala Pharmaceuticals Inc....
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...a very selective buying opportunity. For instance, Linimeier said his firm added a position in Kala Pharmaceuticals Inc....
BioCentury | Mar 12, 2020
Finance

March 11 Quick Takes: PDL, Kala, InnoCare, LifeSci, BioSight, BillionToOne, SEC

...Officer and acting CFO Edward Imbrogno will become the permanent CFO. Kala raises $126M follow-on Kala Pharmaceuticals Inc....
...that they will utilize the extension and summarizing why it is needed. BioCentury Staff InnoCare Pharma Ltd. BioSight Ltd. Kala Pharmaceuticals Inc. PDL...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...of $40.78 on Tuesday, before the takeout was announced. Setback for Kala’s dry eye treatment Kala Pharmaceuticals Inc....
...etabonate mucosal penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala Pharmaceuticals Inc. miRagen...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...assessed to be at imminent risk for suicide Phase III data; submit sNDA 2H19; 4Q19 Kala Pharmaceuticals Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA) PDUFA date 3/20/19 Kala Pharmaceuticals Inc....
BioCentury | Dec 26, 2018
Company News

FDA accepts Acer, Kala NDAs before funding lapse

...FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial...
...up 17% to $5.02. Allison Johnson Edsivo, celiprolol (ACER-002) Inveltys, LE-MPP, Loteprednol etabonate mucosal penetrating particle (KPI-121) Acer Therapeutics Inc. Kala Pharmaceuticals Inc. Adrenergic...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...sleepiness in patients with obstructive sleep apnea and narcolepsy PDUFA date; submit MAA 12/20/18; YE18 Kala Pharmaceuticals Inc....
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy Kala Pharmaceuticals Inc....
Items per page:
1 - 10 of 56